NOV 04, 2020 5:11 AM PST

Damaging Antibodies Can Lead to Blood Clots in COVID-19 Patients

WRITTEN BY: Carmen Leitch

COVID-19, the illness caused by the pandemic virus SARS-CoV-2, is known to cause blood clots all over the body in some patients. These blood clots can lead to serious complications. Scientists have now learned that the virus triggers the production of an autoimmune antibody that can attack cells. As the body moves to repair the damage caused by these attacks in arteries, veins, and tiny vessels, blood clots can occur. Depending on where they happen, these clots can lead to other problems like the impairment of blood flow in the lungs or strokes.

This scanning electron microscope image shows SARS-CoV-2 (orange)-also known as 2019-nCoV, the virus that causes COVID-19-isolated from a patient in the U.S., emerging from the surface of cells (green) cultured in the lab. Image captured and colorized at NIAID's Rocky Mountain Laboratories (RML) in Hamilton, Montana. / Credit: NIAID

The autoantibodies identified in this study have been observed before, but usually in an autoimmune disorder called antiphospholipid syndrome. These findings, which have been reported in Science Translational Medicine, were unexpected, said the co-corresponding study author, Yogen Kanthi, M.D., an assistant professor at the Michigan Medicine Frankel Cardiovascular Center and a Lasker Investigator at the National Institutes of Health's National Heart, Lung, and Blood Institute.

"In patients with COVID-19, we continue to see a relentless, self-amplifying cycle of inflammation and clotting in the body," said Kanthi. "Now we're learning that autoantibodies could be a culprit in this loop of clotting and inflammation that makes people who were already struggling even sicker."

"Half of the patients hospitalized with COVID-19 were positive for at least one of the autoantibodies, which was quite a surprise," added co-corresponding study author Jason Knight, M.D., Ph.D., a rheumatologist and associate professor of internal medicine at Michigan Medicine.

This work revealed that around half of the patients they studied, who had serious COVID-19 cases, carried both high levels of these damaging autoantibodies as well as super-activated forms of white blood cells called neutrophils, which can also cause problems. This research team has previously shown that there are high levels of neutrophil extracellular traps (which can help protect against infection but are also involved in autoimmune disorders sometimes) in the blood of patients with severe COVID-19.

When a mouse model was exposed to a combination of these super-activated neutrophils and the autoantibodies, serious blood clots occurred.

"Antibodies from patients with active COVID-19 infection created a striking amount of clotting in animals - some of the worst clotting we've ever seen," Kanthi said. "We've discovered a new mechanism by which patients with COVID-19 may develop blood clots."

Now the research team wants to investigate whether severe COVID-19 cases might be improved if these autoantibodies are eliminated or blocked.

"We know people with the highest levels of autoantibodies did worse in terms of respiratory function, and the antibodies caused inflammation even in healthy cells," said the first author of the study Yu (Ray) Zuo, M.D., an assistant professor of internal medicine and a rheumatologist at Michigan Medicine.

More work will be needed before we know if such a treatment might work. "We don't yet know what is triggering the body to produce these antibodies, so the next step would be additional research to identify the triggers and the targets of the antibodies," added Knight.

This study also shows that there could be drawbacks to the use of convalescent plasma as a COVID-19 treatment, but again, more research is needed to understand the risks.

"We're now investigating how long these antibodies remain in circulation after recovery from the novel coronavirus," Knight said.

Right now, the team is also assessing whether an anti-clotting agent called dipyridamole can reduce clots in COVID-19 patients.

"Dipyridamole is an old drug that is safe, inexpensive, and scalable," Kanthi said. "The FDA approved it 20 years ago to prevent clotting, but we only recently discovered its potential to block this specific type of inflammation that occurs in COVID."

Sources: AAAS/Eurekalert! Via Michigan Medicine - University of Michigan, Science Translational Medicine

About the Author
  • Experienced research scientist and technical expert with authorships on over 30 peer-reviewed publications, traveler to over 70 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
JUN 05, 2021
Coronavirus
Newly-Named Coronavirus Variant Causes Concern
JUN 05, 2021
Newly-Named Coronavirus Variant Causes Concern
WHO has decided to create a new naming system for coronavirus variants for several reasons. The names will now be based ...
JUN 16, 2021
Technology
Online App Increases Health Literacy and Reduces Vaccine Hesitancy in Incarcerated Women
JUN 16, 2021
Online App Increases Health Literacy and Reduces Vaccine Hesitancy in Incarcerated Women
Many women released from prison are returning to communities hit hard by the COVID-19 pandemic, communities that also fa ...
AUG 11, 2021
Technology
Machine Learning Offers New Way to Detect COVID-19 Infection
AUG 11, 2021
Machine Learning Offers New Way to Detect COVID-19 Infection
Reverse Transcription Polymerase Chain Reaction (RT-PCR) tests have emerged as the standard for testing and confirming C ...
SEP 03, 2021
Cell & Molecular Biology
Is a Venom-Like Molecule Involved in COVID-19 Mortality?
SEP 03, 2021
Is a Venom-Like Molecule Involved in COVID-19 Mortality?
Scientists have sought to learn more about why some people get severe COVID-19 while others have only mild cases. We kno ...
SEP 07, 2021
Health & Medicine
Vaccines- a Long History of Cost-Benefit Analysis
SEP 07, 2021
Vaccines- a Long History of Cost-Benefit Analysis
Vaccination and new treatments for diseases have remained topics of skepticism since their inception. When it came to an ...
SEP 16, 2021
Chemistry & Physics
American Astronomical Society Commits to Open Access Journals
SEP 16, 2021
American Astronomical Society Commits to Open Access Journals
The American Astronomical Society (AAS) will move to open access format by January 1, 2022. AAS publishes six journals: ...
Loading Comments...